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New therapeutic options are being considered to treat genitourinary syndrome of 
menopause (GSM), such as vaginal laser, ospemifene, or prasterone, but there is 
no explicit agreement in the scientific community for its use. Some concerns have 
arisen on how to evaluate the improvement of GSM symptoms. In 2003, the FDA 
suggested possible end points for this purpose: change in severity of symptoms, 
change in vaginal pH, and change in vaginal maturation index (VMI). Contrarily, 
the most common assessment tools used to quantify severity and improvement 
of GSM nowadays are the visual analog scale of GSM symptoms, the vaginal 
health index, and the female sexual function index. In our opinion, subjective and 
objective variables to evaluate GSM can be differentiated, and not many of the 
considered objective outcomes are used in the recent literature assessing GSM. 
There is the possibility that some therapies present only subjective improvement, 
giving place to a possible placebo effect that is not being evaluated. To conclude, 
there is a demand to evaluate whether vaginal pH and VMI are enough to assess 
objectively GSM changes or new objective approaches should be audited.
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these new options. However, to date, there is no explicit 
agreement in the scientific community for its use, since, 
in 2018, the FDA published an alert highlighting that the 
efficacy and safety of vaginal laser treatments had not 
been established.[4]
Furthermore, some concerns have arisen on evaluating 
the improvement of GSM symptoms when any of the 
mentioned treatments are used. The assessment tools to 
measure the success or benefit for each treatment remain 
a critical hot topic, underlining the lack of consensus 
among researchers on how we are assessing clinically 
relevant changes in women presenting with GSM.[5]
Previously, the FDA had summarized possible end 
points, including change in the severity of symptoms, 
Review Article
Introduction
Genitourinary syndrome of menopause (GSM) collects different symptoms and signs related to 
decreased blood circulating estrogens, comprising from 
urinary tract symptoms, vaginal dryness, and irritation to 
dyspareunia and sexual symptoms, provoking to up to 
50% of those who suffer it, causing impairment in the 
quality of life.[1,2]
Mild GSM is usually treated using nonhormonal 
lubricants and moisturizers, but those present doubtful 
benefits when facing severe GSM symptoms. The logical 
treatment to palliate the lack of estrogen is using local 
estrogen products demonstrated to be the most effective 
therapy.
Lately, new therapeutic options are being considered to 
treat GSM symptoms, such as vaginal laser, ospemifene, 
or prasterone, potential alternatives for those patients 
where estrogenic therapies are not recommended.[3]
A vast amount of literature is emerging, primarily related 
to vaginal laser, assessing the safety and efficacy of 
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change in vaginal pH, and change in vaginal maturation 
index (VMI).[6]
This review aims to summarize the present evidence on 
the diagnostic and assessment tools to evaluate GSM.
Diagnosis of Genitourinary Syndrome 
of Menopause
The classical diagnostic modality for GSM has been 
a “clinical diagnosis,” including a clinical suspicion 
when women in menopausal status present symptoms 
such as burning, dryness, and dyspareunia in the genital 
tract, and is confirmed through a clinical exploration, 
observing a pale and dry vulvovaginal mucosa usually 
with petechiae. It is essential to differentiate from other 
vaginal conditions that mimic bothersome vaginal 
conditions such as vaginal lichen sclerosis, vaginal 
lichen planus, hyperkeratosis, contact dermatitis, 
vulvar cancer, and vulvar cancer vulvar intraepithelial 
neoplasm, extramammary Paget disease, and vaginal 
infections.[7]
Since the clinical diagnosis of GSM started through a 
report of symptoms from the patients, during the last 
decades, the GSM diagnosis has been underdiagnosed 
due to an underreport from patients and unawareness 
from professionals to seek this problem.[8]
Thereafter, when the diagnosis of GSM is made, a 
cascade of different treatments starts. The assessment of 
the GSM improvement was classically made clinically, 
changing to the next therapeutic step if the women 
reported no changes.
Today, we are entering a new era where physicians 
have on board novel therapies such as vaginal laser, 
prasterone, or ospemifene. Yet, there is no consensus 
on how to use them. We believe that it is a vital issue 
to acquire well-designed assessment tools to precisely 
evaluate the severity of GSM and its improvement 
when using any treatment, through either subjective 
or objective tests. The implementation of reliable 
assessment tools would ultimately bring consistency 
across scientific evaluation of GSM, allowing to regulate 
the treatment indications.
Assessment Tools for Genitourinary 
Syndrome of Menopause
Considering many studies conducted up to date regarding 
GSM evaluation, the most common assessment tools 
used to quantify severity and improvement of GSM 
are the visual analog scale (VAS) of GSM symptoms, 
the vaginal health index (VHI), and the female sexual 
function index (FSFI) patient-reported outcomes 
measure (PROM).
Depending on the target for each assessment tool, a 
classification of subjective outcomes and objective 
outcomes was made:
Assessment tools that considered subjective outcomes, 
influenced by the patient perception of the complaint, 
are the most widely used in the scientific evaluation 
of GSM. Among them, we find the VAS of GSM 
symptoms evaluation and different PROMS such as 
the FSFI, assessing six domains of sexuality: desire, 
arousal, lubrication, orgasm, satisfaction, and pain, 
and the 12-Item Short Form Survey, which is a 
health-related quality-of-life questionnaire consisting 
of 12 questions that measure eight health domains 
to assess physical and mental health, among others 
[Figure 1].
It is to note that there is a disagreement on considering 
VHI, a clinical medical evaluation, as a subjective or 
objective measure. Some authors consider the VHI an 
objective measure. Suppose we disaggregate this overall 
score, in that case, we can observe that in 4 out of 
5 variables of the index (vaginal elasticity, fluid volume, 
epithelial integrity, and moisture), the judgment of the 
clinical status from the physician is in some manner 
subjective, remaining just one objective variable which 
is the vaginal pH measurement.[9]
Figure 1: Summary of current and potential assessment 
tools











AT: Assessment tools, VAS: Visual Analog Scale on GSM 
symptoms, FSFI: Female sexual function index (De: Desire, 
Ar: Arousal, Lu: Lubrication, Or: Orgasm, Sa: Satisfaction, Pa: 
Pain), SF12: Health-related quality-of-life questionnaire (Ph: 
Physic [Physical function, physical role, corporal pain, general 
health], Me: Mental [vitality, social function, emotonial role, 
mental health]), VHI: Vaginal health index (Fv: Fluid volume, Ela: 
Elasticity, EI: Epitelial integrity, Mo: Moisture), VMI: Vaginal 
maturation index, VTb: Vaginal epithelial thickness on biopsy, 
VLP: Vaginal lamina propia characteristics on biopsy (∆FCVK: 
Increased number of fibroblasts, increased amount of collagen, 
increased degree of vascularization and increase of Ki67), VTu: 
Vaginal thickness on abdominal ultrasound measure, VC: Vaginal 
compliance on biopsy (tensile strength), GSM: Genitourinary 
syndrome of menopause
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Instead, not many of the considered objective outcomes 
are used in the recent literature assessing GSM. The 
most frequently used is the vaginal pH measurement, 
recommended since 2003 by the FDA for GSM 
assessment, and used as a part of the VHI calculation. To 
assess pH, a piece of litmus paper is placed on the lateral 
vaginal wall until moistened. A pH of 4.6 or greater 
indicates vulvovaginal atrophy (VVA), assuming the 
patient does not have bacterial vaginosis. Premenopausal 
women without VVA typically have a pH of 4.5 or less.[10]
Another recommended outcome in the 2003 FDA 
recommendation to GSM evaluation was the VMI, 
which has not been as successful in the literature as 
the VHI, considering that it is not usually found in 
most studies assessing GSM.[11] The VMI assesses 
the relative proportion of parabasal, intermediate, and 
superficial vaginal epithelial cell types in a vaginal 
cytology sample. In premenopausal women, greater than 
15% of superficial cells would be considered normal; 
however, in postmenopausal women with VVA, the 
typical proportion would be less than 5%. The VMI is 
usually calculated according to the formula, maturation 
value: (0 × % of parabasal cells) × (0.5 × % of 
intermediate cells) × (1.0 × % of superficial cells).[12]
Other objective outcomes had been proposed but scarcely 
used and only reported in case series studies. Some 
authors studied vaginal epithelial thickness, composition 
of the lamina propria, and vaginal compliance: Salvatore 
et al. performed an ex vivo histological study on the 
effects of microablative fractional CO2 laser on atrophic 
vaginal samples from five women, concluding that laser 
can produce a remodeling of vaginal connective tissue 
without causing damage surrounding tissue.[13]
Contrarily, Mackova et al. presented the data from a 
preclinical trial where pathology analysis was performed 
to an animal model (ewe), including vaginal thickness, 
composition of lamina propria, and vaginal compliance, 
concluding that YAG laser had a comparable increase 
in vaginal epithelial thickness to sham manipulation in 
menopausal ewes and none of the interventions induced 
changes in the vaginal lamina propria.[14]
Finally, few authors attempted to objectively evaluate 
transvaginal ultrasound to measure the vaginal wall 
thickness in GSM, suggesting that it could be effective 
as a histological measurement.[15] Being a promising line 
of investigation since would bring objectiveness through 
a noninvasive exploration.
Conclusion
The literature on assessing GSM objectively is scant, 
and there is a need to develop an objective model for 
the most appropriate assessment for GSM. From our 
perspective, there is a demand to evaluate whether 
vaginal pH and VMI are enough to assess objectively 
GSM changes or new approaches should be audited.
Although different techniques to evaluate GSM in 
the actual scientific literature will appear, consistency 
among studies and clinical trials is needed to facilitate 
comparisons of results. In our opinion, subjective and 
objective variables to evaluate GSM can be differentiated. 
There is the possibility that some therapies present only 
subjective improvement, giving place to a possible 
placebo effect. In addition, there is the possibility to find 
some options where objective outcomes improve with 
the absence of subjective assessment tools improvement 
and therefore may be opening the door to complimentary 
nonphysical therapies.
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